Professional Documents
Culture Documents
when the organism is S. aureus, a gram-negative bacillus, or a fungus), surgery may be required after only 24 to 72 h of antimicrobial therapy. In patients with prosthetic valves, surgery may be required when TEE shows
PenicillinPenicillin G 1218 million units/day Ceftriaxone 2 g once/day IV for 4 wk susceptible strepto- IV continuously or 23 million or, if gentamicin 1 mg/kg* IV (up to cocci (penicillin G units q 4 h for 4 wk or, if gentami- 80 mg) q 8 h is given concurrently, for MIC 0.1 g/mL), cin 1 mg/kg* IV (up to 80 mg) q 2 wk through a central venous catheincluding most vir- 8 h is given concurrently, for 2 wk ter (can be given on outpatient basis) idans streptococci if there is no history of penicillin anaphylaxis or Vancomycin 15 mg/kg IV q 12 h for 4 wk Streptococci relaGentamicin 1 mg/kg* IV q 8 h plus Desensitization to penicillin tively resistant to penicillin G 1830 million units/ or penicillin (penicil- day IV or ampicillin 12 g/day IV Vancomycin 15 mg/kg IV (up to 1 g) lin G MIC > 0.1 g/ continuously or 2 g q 4 h for q 12 h plus gentamicin 1mg/kg* IV q mL), including en- 46 wk 8 h for 46 wk terococci, some other streptococcal strains, and Abiotrophia defectiva (previously S. defectivus) Pneumococci or Penicillin G 1218 million units/ Ceftriaxone 2 g once/day IV for 4 wk group A streptoday IV continuously for 4 wk if through a central venous catheter (can cocci susceptible to penicillin be given on outpatient basis) if there is or no history of penicillin anaphylaxis Vancomycin 15 mg/kg IV q 12 h or for 4 wk for pneumococci with Vancomycin 15 mg/kg IV q 12 h for penicillin G MIC 2 g/mL 4 wk
Table continues on the following page.
Coliform bacilli
Pseudomonas aeruginosa
For patients with a left-sided native Cefazolin 2 g IV q 8 h for 46 wk valve: Oxacillin or nafcillin 2 g IV if staphylococci are susceptible to oxacillin or nafcillin and if there is q 4 h for 46 wk For patients with a right-sided na- no history of penicillin anaphylaxis or tive valve: Oxacillin or nafcillin 2 g IV q 4 h for 24 wk plus gen- Cefazolin 2 g IV q 8 h for 24 wk plus tamicin 1 mg/kg* IV q 8 h for 2 wk gentamicin 1 mg/kg* IV q 8 h for 2 wk or For patients with a prosthetic valve: Cefazolin 2 g IV q 8 h for 46 wk plus Oxacillin or nafcillin 2 g IV q 4 h for 68 wk plus gentamicin gentamicin 1 mg/kg* IV q 8 h for 2 wk plus rifampin 300 mg po q 8 h for 1 mg/kg* IV q 8 h for 2 wk plus 68 wk rifampin 300 mg po q 8 h for or 68 wk Vancomycin 15 mg/kg IV q 12 h alone if native valve, plus gentamicin 1 mg/ kg* IV q 8 h for 2 wk plus rifampin 300 mg po q 8 h for 46 wk if prosthetic valve Vancomycin 15 mg/kg IV q 12 h alone if native valve, plus gentamicin 1 mg/kg IV* q 8 h for 2 wk plus rifampin 300 mg po q 8 h for 68 wk if prosthetic valve Ceftriaxone 2 g once/day IV for Ceftriaxone 2 g once/day IV for 4 wk 4 wk or, if gentamicin 1 mg/kg* IV (up to or 80 mg) q 8 h is given concurrently, for Ampicillin 12 g/day IV continu2 wk if there is no history of penicillin ously or 2 g q 4 h plus gentamicin anaphylaxis 1 mg/kg* IV q 8 h for 4 wk Sensitivity-proven -lactam anti- microbial (eg, ceftriaxone 2 g IV q 1224 h or ceftazidime 2 g IV q 8 h) plus an aminoglycoside (eg, gentamicin 2 mg/kg* IV q 8 h) for 46 wk Ceftazidime 2 g IV q 8 h or cefepime Ceftazidime 2 g IV q 8 h or cefepime 2 g IV q 8 h or imipenem 500 mg 2 g IV q 8 h plus tobramycin 2.5 mg/ IV q 6 h plus tobramycin 2.5 mg/kg kg q 8 h for 68 wk; amikacin 5 mg/kg q 8 h for 68 wk; amikacin 5 mg/kg q 12 h substituted for tobramycin q 12 h substituted for tobramycin if if bacteria are susceptible only to bacteria are susceptible amikacin
*Based on ideal rather than actual weight in obese patients. With vancomycin, serum levels must be monitored if doses > 2 g/24 h are administered. If enterococcal endocarditis lasts > 3 mo and involves large vegetations or vegetations on prosthetic valves, treatment should last for 6 wk. Some clinicians add gentamicin 1 mg/kg IV q 8 h for 35 days if patients have a native valve. HACEK microorganisms: Haemophilus parainfluenzae, H. aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
Copyright 2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J. U.S.A.